Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR1 Vaccine with Montanide ISA 51 in Myeloid Leukemias
NCT00004918Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 1999
- Primary completion
- Dec 2007
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PR1 leukemia peptide vaccine in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started Dec 1999; status: completed.
02
Drugs
PR1 leukemia peptide vaccine
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00004918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004918.